Trovagene (TROV) says ongoing clinical studies suggest the company's technology is applicable "across a variety of cancer types." The company also announces clinical validation of an assay procedure for the detection of oncogenic mutations in cancer patients' urine. "The … capability to non-invasively monitor a patients' cancer in near-real time may improve … overall [disease] management, leading to better patient outcomes," CEO Antonius Schuh says. Shares +6.5% premarket. (PR)
Trovagene (TROV) says ongoing clinical studies suggest the company's technology is applicable...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs